Personalizing Blood Cancer Treatment
Huge advances have been made in the understanding of multiple myeloma. There are a variety of approaches for treating this blood cancer. The trick is to provide what’s best for the individual patient.
Closing In on a Cure
Someone diagnosed with any type of leukemia in the early 1960s had about a 14 percent chance of being alive five years later. Today, those chances are vastly greater.
New Rx for Advanced Multiple Myeloma
Multiple myeloma is a blood cancer that affects nearly 22,000 Americans every year. It develops in mostly older people when plasma cells in the bone marrow grow out of control.
Revlimid and Risk of New Cancers
The U.S. Food and Drug Administration (FDA) is informing the public of an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received Revlimid ( lenalidomide ).
Cancer Rx Linked to Second Cancers
Health Canada, the Canadian version of the U.S. Food & Drug Administration (FDA), has issued an alert regarding the medication REVLIMID ( lenalidomide ) that's used to treat multiple myeloma .